Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (22)

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  3. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  4. Macrophage re-programming by JAK inhibitors relies on MAFB

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

  5. Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center

    BMC Musculoskeletal Disorders, Vol. 25, Núm. 1

2023

  1. Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey'

    Annals of the Rheumatic Diseases

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT

    RMD open, Vol. 9, Núm. 3

  4. Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study

    Rheumatology International, Vol. 43, Núm. 7, pp. 1333-1340

  5. Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care

    RMD open, Vol. 9, Núm. 2

  6. The role of ultrasound and FDG-PET/CT to detect extracranial artery involvement in patients with suspected large vessel vasculitis

    Modern rheumatology, Vol. 33, Núm. 3, pp. 549-556

2022

  1. Impact of cardiovascular risk on the diagnostic accuracy of the ultrasound Halo Score for giant cell arteritis

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  2. Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges

    Infectious Diseases and Therapy, Vol. 11, Núm. 5, pp. 2017-2033

  3. Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases

    BMC Musculoskeletal Disorders, Vol. 23, Núm. 1

  4. Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

    Musculoskeletal Care, Vol. 20, Núm. 2, pp. 403-407

  5. Ultrasound intima media thickness cut-off values for cranial and extracranial arteries in patients with suspected giant cell arteritis

    Frontiers in Medicine, Vol. 9

2021

  1. Clinical impact of confinement due to the COVID-19 pandemic on patients with fibromyalgia: A cohort study

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3

  2. Subclavian artery involvement in patients with giant cell arteritis: do we need a modified Halo Score?

    Clinical Rheumatology, Vol. 40, Núm. 7, pp. 2821-2827

  3. The importance of outcome measures in the management of inflammatory rheumatic diseases

    Open Access Rheumatology: Research and Reviews, Vol. 13, pp. 191-200

  4. Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development

    Arthritis Research and Therapy, Vol. 23, Núm. 1